Group 1 - The treatment level for lymphoma, particularly Diffuse Large B-cell Lymphoma (DLBCL), has significantly improved over the past 20 years, with a 5-year overall survival rate exceeding 60% [1] - Despite advancements, a considerable number of newly diagnosed DLBCL patients do not achieve complete remission after standard treatment (R-CHOP regimen) and face a high risk of relapse [1] - The development of precision-targeted therapies has diversified treatment options, leading to improved outcomes for previously poorly responding DLBCL patients [1] Group 2 - Traditional efficacy assessment for lymphoma relies on PET-CT imaging, which has limitations such as increased radiation dose and difficulty in distinguishing between active immune cells and tumor lesions [2] - PET-CT assessments are typically conducted only after three and six treatment cycles, hindering early detection of treatment failures [2] - Liquid biopsy technology based on circulating tumor DNA (ctDNA) is being explored for its clinical application, as ctDNA can serve as a molecular marker for tumor burden and treatment response [2] Group 3 - Shanghai Ruian Gene Technology Co., Ltd. has developed a "B-cell lymphoma ctDNA detection kit" with patented probes and algorithms, showing promising research results in collaboration with Ruijin Hospital [3] - The kit allows for the assessment of DLBCL patients' responses to standard treatment after just one treatment cycle, and pre-treatment ctDNA detection can predict early chemotherapy failure [3] - The successful development of this detection kit is expected to advance clinical trials and enhance precision diagnosis and treatment for lymphoma patients in China once approved by the National Medical Products Administration (NMPA) [3]

Core Viewpoint - Ruiang Gene (688217.SH) reported a significant decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters of 2025 was 139 million yuan, representing a year-on-year decrease of 26.64% [1] - The net profit attributable to shareholders of the parent company was -5.62 million yuan, compared to a net profit of 5.73 million yuan in the same period last year [1] - The basic earnings per share were -0.1 yuan [1]

根据《企业会计准则》以及上海睿昂基因科技股份有限公司（以下简称"公 司"）会计政策、会计估计的相关规定，为了真实、准确地反映公司 2025 年第 三季度的财务状况和经营成果，本着谨慎性原则，对 2025 年 7 月 1 日至 2025 年9月30日公司及子公司相关信用及资产进行了减值测试并计提了相应的减值 准备。2025 年第三季度公司拟计提各类信用及资产减值准备共计 3,244,068.70 元。具体情况如下： 证券代码：688217 证券简称：睿昂基因 公告编号：2025-051 上海睿昂基因科技股份有限公司 关于 2025 年第三季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提减值准备情况概述 三、计提减值准备对公司的影响 2025 年第三季度公司合并报表口径计提各类信用减值损失、资产减值损失 减值准备合计 3,244,068.70 元，减少公司 2025 年第三季度利润总额影响数 3,244,068.70 元（合并利润总额未计算所得税影响）。 公司 2025 年第三季度计提资产减 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2025-049 上海睿昂基因科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事成员保证公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、拟聘任会计师事务所的基本情况 组织形式：特殊普通合伙 注册地址：杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室 （一）机构信息 1、基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于 杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服 务业务。 事务所名称：中汇会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 19 日 首席合伙人：高峰 上年度末（2024 年 12 月 31 日）合伙人数量：116 人 上年度末（2024 年 12 月 31 日）注册会计师人数：694 人 上年度末（2024 年 12 月 31 日）签署过证券服务业务审计报告的注册会计 拟聘任的会计师事务所名称：中汇会计师事务所（特殊普通合伙）（以 下简称"中汇会计师事务所" ...

一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第四次临时股东会 召开日期时间：2025 年 11 月 14 日 14 点 30 分 证券代码：688217 证券简称：睿昂基因 公告编号：2025-050 上海睿昂基因科技股份有限公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 召开地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 14 日 至2025 年 11 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 股东会召开日期：2025年11月14日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次 ...

Financial Performance - The company's operating revenue for the third quarter was ¥34,355,268.37, a decrease of 37.35% compared to the same period last year[4] - The total profit for the third quarter was -¥13,160,358.53, with a year-to-date total profit of -¥16,512,859.59[4] - The net profit attributable to shareholders for the third quarter was -¥9,174,959.22, representing a 198.14% increase in losses year-to-date[4] - Total operating revenue for the first three quarters of 2025 was CNY 139,103,619.10, a decrease of 26.6% compared to CNY 189,630,100.09 in the same period of 2024[21] - Net profit for the first three quarters of 2025 was a loss of CNY 12,308,952.88, compared to a profit of CNY 1,547,536.52 in the same period of 2024[22] - The company reported a basic and diluted earnings per share of CNY -0.10 for the first three quarters of 2025, compared to CNY 0.10 in 2024[23] - Basic and diluted earnings per share for the third quarter were both -¥0.17, a decrease of 200% compared to the previous year[5] Research and Development - Research and development expenses totaled ¥10,801,929.03 for the quarter, accounting for 31.44% of operating revenue, an increase of 8.37 percentage points[5] - Research and development expenses for the first three quarters of 2025 were CNY 42,449,127.26, down 9.7% from CNY 46,854,439.70 in 2024[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥947,826,923.07, a decrease of 3.84% from the end of the previous year[5] - Total current assets as of September 30, 2025, amount to ¥440,132,705.37, a decrease from ¥470,136,956.05 as of December 31, 2024[17] - Total assets amount to ¥947,826,923.07, down from ¥985,701,603.79[17] - The total liabilities decreased to CNY 39,491,403.37 in 2025 from CNY 65,057,131.21 in 2024, reflecting a reduction of 39.2%[19] - The total equity attributable to shareholders decreased to CNY 903,635,431.60 in 2025 from CNY 909,256,093.84 in 2024, a decline of 0.7%[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥26,861,231.93, a decrease of 17.60% compared to the previous year[4] - The company's cash flow from operating activities for the first three quarters of 2025 was CNY 156,046,434.85, a decrease of 19.8% from CNY 194,589,393.22 in 2024[25] - The net cash flow from operating activities was $26,861,231.93, a decrease of 17.4% compared to $32,599,551.94 in the previous period[26] - Total cash inflow from investment activities was $154,094,855.46, down from $181,198,809.30, reflecting a decline of 15%[26] - The net cash flow from investment activities was -$30,164,097.45, an improvement from -$36,834,773.43 in the previous period[26] - Cash outflow from financing activities totaled $18,199,331.59, slightly decreased from $19,766,138.25[27] - The net increase in cash and cash equivalents was -$21,961,958.45, compared to -$24,532,157.77 in the previous period[27] - Cash outflow for purchasing goods and services was $31,790,293.19, compared to $37,921,991.98 previously, indicating a decrease of 16.5%[26] - Cash paid to employees was $60,546,569.70, down from $70,624,800.75, a reduction of 14.4%[26] - Cash paid for taxes increased to $17,337,356.89 from $11,673,215.72, representing a rise of 48.5%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 4,715[12] - The largest shareholder, Xiong Hui, holds 10,176,397 shares, representing 18.22% of total shares[12] Impairment and Competition - The company reported an increase in accounts receivable credit impairment losses by 30.92% year-on-year, amounting to ¥5,052,650[10] - The company experienced a significant increase in credit impairment losses, which rose to CNY -7,222,974.28 in 2025 from CNY -5,517,111.95 in 2024[22] - The company experienced intensified competition in the in vitro diagnostics industry, impacting revenue negatively[9] Accounting Standards - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[28]

Core Viewpoint - Ruiang Gene announced a cash dividend of 0.17 yuan per share (including tax) for the first half of 2025, with the record date set for October 23, 2025, and the ex-dividend date on October 24, 2025 [1] Summary by Relevant Sections - Dividend Announcement - The company will distribute a cash dividend of 0.17 yuan per share for the first half of 2025 [1] - The dividend is inclusive of tax [1] - Important Dates - The record date for shareholders to be eligible for the dividend is October 23, 2025 [1] - The ex-dividend date, when the stock will trade without the dividend, is October 24, 2025 [1]

上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 差异化分红的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 关于上海睿昂基因科技股份有限公司 差异化分红的 法律意见书 案号：01G20231416 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"锦天城"或"本所"）接受上海睿昂 基因科技股份有限公司（以下简称"公司"或"睿昂基因"）的委托，就公司 2025 年半年度利润分配所涉及的差异化分红（以下简称"本次差异化分红"） 相关事项出具本法律意见书。 为出具本法律意见书，本所律师查阅了公司本次差异化分红的有关文件和材 料，就相关事项向公司进行了必要的询问。本所根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股份回购规则》（以下简称"《回购规则》"）、《上海 证券交易所上市公司自律监管指引第 7 号——回购股份》（以下简称"《回购 指 ...

2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688217 证券简称：睿昂基因 公告编号：2025-048 上海睿昂基因科技股份有限公司 本次利润分配方案经公司2025 年 9 月 16 日的2025年第二次临时股东大会审议 通过。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.17元 相关日期 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 及其他规范性文件和公司章程的有关规定，公司回购专用证券账户中的股份不享 有股东大会表决权、利润分配、公积金转增股本、认购新股等权利。 3. 差异化分红送转方案： | 股权登记日 ...

Core Points - The third extraordinary general meeting of shareholders for Shanghai Ruian Gene Technology Co., Ltd. was held on October 10, 2025, with no rejected proposals [2] - All resolutions presented at the meeting were approved, including the cancellation of the supervisory board and amendments to the company's articles of association [5][6] Meeting Details - The meeting was convened at the company's conference room located at 1817 Lane 147, Huifeng West Road, Fengxian District, Shanghai [2] - A total of 55,855,896 shares were registered for voting, with 669,621 shares in the company's repurchase account not entitled to vote [2] Attendance - All 8 current directors and 3 current supervisors attended the meeting, along with the company secretary and other executives [4] Resolutions - The following resolutions were passed: - Cancellation of the supervisory board and revision of the articles of association [5] - Amendments to various internal management systems, including information disclosure, fundraising management, and independent director systems [6][7] - The special resolution regarding the cancellation of the supervisory board received more than two-thirds approval from the voting shareholders [7] Legal Verification - The meeting was witnessed by Shanghai Jintiancheng Law Firm, confirming that the convening and proceedings complied with relevant laws and regulations [7]